“Management of Hepatorenal Syndrome: A Review of Current Therapeutic Options”
HealthTrust presents...”Management of Hepatorenal Syndrome: A Review of Current Therapeutic Options”
Please Note: Continuing education credit is only available to those attending the session live. CE credit is not available when accessing the program on demand.
Hepatorenal syndrome (HRS) is a type of acute kidney injury (AKI), known as HRS-AKI, which occurs in patients with cirrhosis in the absence of hypovolemia or significant abnormalities in kidney histology. If left untreated, patients with HRS-AKI have a median survival time of approximately two weeks and greater than 80% mortality within three months with limited treatment options. The purpose of this presentation is to review the pharmacological management of HRS-AKI as recommended by current guidelines and discuss the recent Food and Drug Administration approval of terlipressin and its place in therapy for this indication in the United States.
Learning Objectives for Pharmacists & Nurses | At the end of this session, participants should be able to:
- Recall the pathophysiology and treatment options for hepatorenal syndrome-acute kidney injury (HRSAKI)
- Recognize the mechanism of action and safety considerations for vasoconstrictors in HRS-AKI
- Identify the role of vasoconstrictors in HRS-AKI based on current literature
Learning Objectives for Pharmacy Techs | At the end of this session, participants should be able to:
- Recall dosing and how pharmacologic therapies for hepatorenal syndrome-acute kidney injury (HRS-AKI) are supplied
- Recognize commonly observed adverse reactions associated with vasoconstrictors in HRS-AKI
- Identify challenges in patient management associated with treatment options for HRS-AKI
Niti Shah, PharmD | PGY-2 Critical Care Pharmacy Resident | Atlantic Health System | Summit, NJ
Target Audience: Pharmacists, Pharmacy Techs & Nurses
CE Credit: Approved for Pharmacists, Pharmacy Techs & Nurses
This program is approved for CPEs by the Accreditation Council for Pharmacy Education (ACPE). Attendees of this program may earn 1.0 CPE Contact Hours. Belmont University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Numbers for this activity are 0863-9999-23-048-L01-P (Pharmacists) and 0863-9999-23-048-L01-T (Techs). The activity is approved for 1 hour (.1 CEUs) of continuing education credit for Pharmacists, Pharmacy Techs & Nurses who attend the webinar and complete the online evaluation. Pfiedler Education is a division of AORN, provider approved by the California Board of Registered Nursing, Provider Number CEP13019, for 1 contact hour. 1.0 contact hours approved for Nurses.
Note about CE credit: If you plan to obtain credit for a live session, stay until the end of the presentation to receive the verification code you will need to obtain the continuing education credit. CE credit is individual. No group credit is available. Each person must register for a webinar and attend the webinar in its entirety in order to receive an email after the event with instructions on how to apply for continuing education credit. Attendees should not share the code or forward the email to others who did not actually attend the program. If they are not able to be verified on our webinar provider reports and registration list they will not receive credit. If you are joining only by phone, you will not be eligible for credit. You must also log in and join the visual portion of the webinar to be part of our CE provider-required reporting.